Clinical Study
Transcatheter Mitral Valve Repair in Surgical High-Risk Patients: Gender-Specific Acute and Long-Term Outcomes
Table 3
Postprocedural outcome, clinical variables.
| | | Baseline | Discharge | 12 months | 24 months | | | Men () | Women () | value | Men () | Women () | value | Men () | Women () | value | Men () | Women () | value |
| | Clinical phenotype | | | | | | | | | | | | | | NYHA class No. (%) | | | 0.44 | | | 0.95 | | | 0.44 | | | 0.13 | | I | 0 (0) | 0 (0) | — | 4 (3.0) | 3 (4.0) | 1.0 | 17 (9.7) | 12 (9.8) | 1.0 | 18 (13.7) | 6 (7.0) | 0.18 | | II | 13 (3.6) | 12 (5.3) | 0.44 | 71 (53.4) | 42 (56.0) | 0.83 | 93 (53.1) | 59 (48.4) | 0.49 | 62 (47.3) | 40 (46.5) | 1.0 | | III | 243 (67.9) | 160 (70.8) | 0.51 | 54 (40.6) | 28 (37.3) | 0.75 | 56 (32.0) | 48 (39.3) | 0.24 | 41 (31.3) | 37 (43.0) | 0.11 | | IV | 101 (28.2) | 54 (23.9) | 0.29 | 4 (3.0) | 2 (2.7) | 1.0 | 9 (5.1) | 3 (2.5) | 0.39 | 10 (7.6) | 3 (3.5) | 0.33 | | MLHFQ score | 40.0 (27.0–52.0) | 42.0 (32.0–51.0) | 0.18 | 17.0 (15.0–19.0) | 55.5 (43.8–57.6) | 0.036 | 31.0 (15.0–48.0) | 32.0 (11.0–47.0) | 0.55 | 25.0 (11.0–43.5) | 35.0 (24.0–44.0) | 0.07 | | 6MWD (m) | 215 (79.6–320) | 149 (50.0–243.8) | 0.0011 | 300 (210–350) | 175 (126–300) | 0.0053 | 345 (180–448) | 240 (150–315) | <0.001 | 355 (180–411) | 270 (166–400) | 0.11 | | Laboratory parameters | | | | | | | | | | | | | | NT-proBNP (ng/L) | 4262 (1980–8370) | 3474 (1712–6898) | 0.49 | 4582 (2528–8609) | 3512 (1896–7084) | 0.023 | 2933 (1310–5062) | 2331 (1324–5206) | 0.79 | 2198 (881–4878) | 2170 (1209–4277) | 0.88 | | Troponin T (pg/mL) | 35.0 (21.9–53.0) | 20.0 (12.0–31.0) | <0.001 | 59.0 (39.0–89.0) | 43.0 (28.0–67.3) | <0.001 | 27.0 (18.0–36.0) | 17.0 (10.0–23.0) | <0.001 | 24.0 (18.4–33.0) | 17.0 (12.0–26.3) | 0.0072 | | Creatinine (mg/dL) | 1.5 (1.2–1.9) | 1.2 (0.9–1.4) | <0.001 | 1.4 (1.1–1.8) | 1.0 (0.8–1.3) | <0.001 | 1.5 (1.2–1.9) | 1.3 (1.0–1.6) | <0.001 | 1.5 (1.2–2.1) | 1.14 (1.0–1.7) | <0.001 | | GFR (mL/min) | 48.0 (36.0–62.6) | 47.3 (37.3–63.2) | 0.81 | 53.8 (39.9–70.8) | 57.1 (42.2–72.7) | 0.48 | 49.7 (36.3–61.5) | 41.9 (32.3–56.6) | 0.078 | 46.4 (32.1–62.3) | 48.0 (32.0–57.5) | 0.77 | | AST (U/L) | 26.0 (19.0–34.8) | 24.5 (18.0–33.0) | 0.16 | 24.0 (19.0–32.0) | 22.0 (17.0–28.0) | 0.015 | 24.0 (19.0–29.0) | 22.0 (18.0–27.1) | 0.31 | 23.0 (20.0–29.0) | 24.5 (19.0–28.1) | 0.66 | | ALT (U/L) | 21.0 (14.0–31.8) | 19.0 (12.0–25.0) | 0.018 | 19.0 (12.0–30.0) | 16.0 (12.0–24.0) | 0.038 | 19.0 (14.3–25.0) | 17.0 (14.0–23.0) | 0.25 | 22.0 (15.9–29.0) | 17.5 (13.0–27.1) | 0.28 | | gammaGT (U/L) | 83.0 (45.3–160.7) | 50.0 (31.0–100.3) | <0.001 | 70.5 (40.0–143.75) | 49.0 (28.0–98.0) | <0.001 | 76.0 (36.2–158.0) | 34.0 (23.0–68.0) | <0.001 | 58.0 (35.0–113.5) | 33.5 (24.0–69.8) | 0.0020 | | C-reactive protein (mg/L) | 10.0 (5.0–21.0) | 7.0 (5.0–13.8) | 0.014 | 20.0 (12.0–43.0) | 19.0 (12.0–37.2) | 0.22 | 8.0 (5.0–13.0) | 5.0 (5.0–12.1) | 0.22 | 6.5 (5.0–13.0) | 5.0 (5.0–10.3) | 0.41 |
|
|
MLHFQ = Minnesota Living with Heart Failure Questionnaire; 6MWD = six-minute walking distance; NYHA = New York Heart Association; NT-proBNP = N-terminal probrain natriuretic peptide; GFR = glomerular filtration rate; AST = aspartate transaminase; ALT = alanine aminotransferase; and gammaGT = gamma glutamyl transferase.
|
